Investors: Release Details

Valencia, CA, USA, and Melbourne, Australia, 19 March 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), in accordance with ASX Listing Rule 3.16.1, wishes to advise the appointment of Mr Mark Licciardo and Ms Kate Goland of Mertons Corporate Services as Joint Company Secretaries, effective today. As such, Mr Gabriel Chiappini has resigned as Company Secretary.

The Board acknowledges the contribution that Mr Chiappini has made during his tenure as Company Secretary.

As required under ASX Listing Rule 3.14, the Company’s Registered Office is now: C/- Mertons Corporate Services Pty Ltd

Level 7

330 Collins Street

Melbourne VIC 3000

###

ABOUT AVITA MEDICAL LIMITED: AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. Avita’s patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patient’s own skin. Our medical devices work by preparing a Regenerative Epithelial Suspension (RES™), an autologous suspension comprised of the patient’s own skin cells and wound healing factors that are necessary to regenerate natural healthy skin. This autologous suspension is then sprayed onto the areas of the patient to be treated.

In the United States, RECELL® is an investigational device limited by federal law to investigational use. In September 2017, Avita submitted to the United States Food & Drug Administration (FDA) a PMA application for RECELL for the treatment of burn injuries.

In all countries outside of Europe, our portfolio is marketed under the RECELL® brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. RECELL® is TGA-registered in Australia, and CFDA-cleared in China.

In Europe, our portfolio of medical device products received CE-mark approval as three tailored product presentations, with three individual brand names. RECELL® is designed for the treatment of burns and plastic reconstructive procedures; ReGenerCell™ has been formulated for chronic wounds including leg and foot ulcers; and ReNovaCell™ is tailored for aesthetic applications including the restoration of pigmentation.

To learn more, visit www.avitamedical.com.

FOR FURTHER INFORMATION: